Provided by Tiger Trade Technology Pte. Ltd.

BioRestorative Therapies, Inc.

0.1967
-0.0218-9.98%
Post-market: 0.1937-0.0030-1.53%19:59 EST
Volume:3.55M
Turnover:706.25K
Market Cap:4.56M
PE:-0.13
High:0.2100
Open:0.2100
Low:0.1900
Close:0.2185
52wk High:2.28
52wk Low:0.1900
Shares:23.16M
Float Shares:20.78M
Volume Ratio:0.25
T/O Rate:17.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4754
EPS(LYR):-1.1565
ROE:-207.73%
ROA:-89.73%
PB:2.08
PE(LYR):-0.17

Loading ...

BioRestorative Therapies Announces $5 Million Offering With Warrants Issued

Reuters
·
Feb 17

BioRestorative Therapies Raises $5 Million in Public Offering with Warrants Exercisable at $0.35

Reuters
·
Feb 14

BioRestorative Announces Closing of $5.0 Million Public Offering

THOMSON REUTERS
·
Feb 14

BioRestorative Therapies Prices $5 Million Offering With Warrants at $0.35

Reuters
·
Feb 12

BioRestorative Therapies Inc - Offering Priced at $0.35 per Share With Warrants

THOMSON REUTERS
·
Feb 12

Biorestorative Announces Positive Outcome From Type B Meeting With FDA

Reuters
·
Feb 11

BioRestorative Therapies Inc: Currently Anticipates That Phase 3 Trial Ind Submission Will Be Made in Second Half of 2026

THOMSON REUTERS
·
Feb 11

BioRestorative Announces Positive Outcome from Type B Meeting with FDA

GlobeNewswire
·
Feb 11

BioRestorative completes patient enrollment in Phase 2 trial of BTRX-100

TIPRANKS
·
Feb 10

BioRestorative Therapies schließt Patientenrekrutierung für Phase-2-Studie zu BRTX-100 bei chronischer lumbaler Bandscheibenerkrankung ab

Reuters
·
Feb 10

BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease

GlobeNewswire
·
Feb 10

BioRestorative Therapies Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation

Reuters
·
Nov 22, 2025

BioRestorative Therapies files to sell 508,592 shares of common stock for holder

TIPRANKS
·
Nov 19, 2025

BioRestorative Therapies Inc - Type B Meeting Scheduled for Mid-December

THOMSON REUTERS
·
Nov 17, 2025

BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease

GlobeNewswire
·
Nov 17, 2025

BioRestorative Therapies Q3 EPS $(0.33) Beats $(0.36) Estimate, Sales $11.800K Miss $460.000K Estimate

Benzinga
·
Nov 13, 2025

BioRestorative Therapies Q3 Net Income USD -3 Million

THOMSON REUTERS
·
Nov 13, 2025

BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Nov 13, 2025

BioRestorative Therapies Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

BioRestorative Therapies Says Granted Japanese Patent Allowance for Stem Cell Technology; Shares Up Pre-Bell

MT Newswires Live
·
Oct 27, 2025